What is DWTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DWTX?

P/E (TTM) is n/a and 52-week range is $1.28 to $7.04 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DWTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DWTX?

The company profile lists net income (TTM) near $-357M, EPS (TTM) near $-10.60 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dogwood Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Alpharetta, Georgia, US, 33.6M shares outstanding, ISIN US92829J2033 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Dogwood Therapeutics Inc

$DWTX

Health Care · Biotechnology

IR Run Scenarios

$1.40

-0.71%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 8 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Employees

Website

dwtx.com/

IPO

2020-12-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)